Portal de Periódicos da CAPES

ElevatederbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer

1994; Wiley; Volume: 73; Issue: 3 Linguagem: Inglês

10.1002/1097-0142(19940201)73

1097-0142

Jorma Isola, Kaija Holli, Heikki Oksa, Yosh Teramoto, Olli Kallioniemi,

Toxin Mechanisms and Immunotoxins

CancerVolume 73, Issue 3 p. 652-658 Original ArticleFree Access Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer Jorma J. Isola M.D., Corresponding Author Jorma J. Isola M.D. University of Tampere, Department of Biomedical SciencesUniversity of Tampere, Department of Biomedical Sciences, PO Box 607 SF-33101, Tampere, Finland===Search for more papers by this authorKaija Holli M.D., Kaija Holli M.D. University Hospital of Tampere, Tampere, FinlandSearch for more papers by this authorHeikki Oksa M.D., Heikki Oksa M.D. University Hospital of Tampere, Tampere, FinlandSearch for more papers by this authorYosh Teramoto Ph.D., Yosh Teramoto Ph.D. Triton Laboratories Inc., Alameda, CaliforniaSearch for more papers by this authorOlli-Pekka Kallioniemi M.D., Olli-Pekka Kallioniemi M.D. University Hospital of Tampere, Tampere, FinlandSearch for more papers by this author Jorma J. Isola M.D., Corresponding Author Jorma J. Isola M.D. University of Tampere, Department of Biomedical SciencesUniversity of Tampere, Department of Biomedical Sciences, PO Box 607 SF-33101, Tampere, Finland===Search for more papers by this authorKaija Holli M.D., Kaija Holli M.D. University Hospital of Tampere, Tampere, FinlandSearch for more papers by this authorHeikki Oksa M.D., Heikki Oksa M.D. University Hospital of Tampere, Tampere, FinlandSearch for more papers by this authorYosh Teramoto Ph.D., Yosh Teramoto Ph.D. Triton Laboratories Inc., Alameda, CaliforniaSearch for more papers by this authorOlli-Pekka Kallioniemi M.D., Olli-Pekka Kallioniemi M.D. University Hospital of Tampere, Tampere, FinlandSearch for more papers by this author First published: 1 February 1994 https://doi.org/10.1002/1097-0142(19940201)73:3 3.0.CO;2-4Citations: 81AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Background. Recent evidence indicates that a soluble fragment of the erbB-2 oncogene product may be released from cell surface and become detectable in the serum of patients with breast cancer. Methods. To study the diagnostic utility of this phenomenon, the authors measured serum erbB-2 levels with a quantitative enzyme-linked immunosorbent assay in 227 preoperative samples from women who underwent breast surgery and in 339 samples from 225 patients with breast cancer during follow-up. Results. Eleven (9%) of 114 preoperative samples from patients with a histologically verified breast cancer and 2 of 113 (1.8%) from patients with benign breast tumors had elevated (greater than 20 U/ml) serum erbB-2 antigen levels. Ten (91%) of the 11 carcinomas and one of the benign tumors from patients with elevated serum erbB-2 levels also showed overexpression of the erbB-2 protein in immunohistochemical analysis of tissue sections. Elevated preoperative serum erbB-2 levels were predominantly found in patients with large tumors, and those with axillary lymph node or distant metastases. Sixty-three of the 339 (19%) follow-up samples had elevated serum erbB-2 antigen levels. Approximately one-third (30.9%) of the samples taken during recurrent disease were serum erbB-2 positive, which is close to the overall overexpression rate of this oncogene. Elevated erbB-2 levels were more common in patients whose disease was not responsive to treatment. Patients with distant metastases had elevate erbB-2 levels more often (40%) than did those with locoregional recurrence (20%). Elevated erbB-2 levels predicted the appearance of metastases within the next 6 months in 10 of 27 (37%) patients. Conclusion. The study's results suggest that assay serum erbB-2 levels may be valuable in the follow-up and monitoring of patients with breast cancer whose primary tumors show erbB-2 overexpression by immunohistochemistry. Citing Literature Volume73, Issue31 February 1994Pages 652-658 ReferencesRelatedInformation